This network meta-analysis reviewed the efficacy and adverse effects of radiotherapy-based combination therapy for patients without targeted epidermal growth factor receptor (EGFR) mutations/anaplastic lymphoma kinase (ALK) gene rearrangement NSCLC BMs, to screen out the therapy with the best efficacy.<h4>Methods</h4>PubMed, Embase, Web of Science, and Cochrane Library were searched from the earliest publication date available to 1 April 2022. This evidence concerns the gene ALK and non-small cell lung carcinoma.